Home/Filings/4/0000899243-19-026634
4//SEC Filing

OYSTER POINT PHARMA I, LLC 4

Accession 0000899243-19-026634

CIK 0001720725other

Filed

Nov 4, 7:00 PM ET

Accepted

Nov 5, 6:05 AM ET

Size

7.6 KB

Accession

0000899243-19-026634

Insider Transaction Report

Form 4
Period: 2019-11-04
Transactions
  • Conversion

    Common Stock, par value $0.001 per share

    2019-11-04+955,392955,392 total
  • Conversion

    Series B Convertible Preferred Stock

    2019-11-04955,3920 total
    Common Stock, par value $0.001 per share (955,392 underlying)
Footnotes (2)
  • [F1]These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date.
  • [F2]Consists of 955,392 shares of common stock beneficially owned by Oyster Point Pharma I, LLC. William J. Link, as a managing partner of Oyster Point Pharma I, L.L.C., may be deemed to share voting and dispositive power over the shares held by Oyster Point Pharma I, LLC.

Issuer

Oyster Point Pharma, Inc.

CIK 0001720725

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001769046

Filing Metadata

Form type
4
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 6:05 AM ET
Size
7.6 KB